Institutional Repository UDD

High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial

Show simple item record Vial, Pablo Valdivieso, Francisca Ferres, Marcela Riquelme, Raul Rioseco, Maria Calvo, Mario Castillo, Constanza Diaz, Ricardo Scholz, Luis Cuiza, Analia Belmar, Edith Hernandez, Carla Martinez, Jessica Lee, Sang-Joon Mertz, Gregory 2017-04-18T15:00:23Z 2017-04-18T15:00:23Z 2013
dc.identifier.citation Clin Infect Dis. 2013 Oct;57(7):943-951 es_CL
dc.identifier.uri es_CL
dc.description.abstract BACKGROUND: Andes virus (ANDV)-related hantavirus cardiopulmonary syndrome (HCPS) has a 35% case fatality rate in Chile and no specific treatment. In an immunomodulatory approach, we evaluated the efficacy of intravenous methylprednisolone for HCPS treatment, through a parallel-group, placebo-controlled clinical trial. METHODS: Patients aged >2 years, with confirmed or suspected HCPS in cardiopulmonary stage, admitted to any of 13 study sites in Chile, were randomized by study center in blocks of 4 with a 1:1 allocation and assigned through sequentially numbered envelopes to receive placebo or methylprednisolone 16 mg/kg/day (≤1000 mg) for 3 days. All personnel remained blinded except the local pharmacist. Infection was confirmed by immunoglobulin M antibodies or ANDV RNA in blood. The composite primary endpoint was death, partial pressure of arterial oxygen/fraction of inspired oxygen ratio ≤55, cardiac index ≤2.2, or ventricular tachycardia or fibrillation within 28 days. Safety endpoints included the number of serious adverse events (SAEs) and quantification of viral RNA in blood. Analysis was by intention to treat. RESULTS: Infection was confirmed in 60 of 66 (91%) enrollees. Fifteen of 30 placebo-treated patients and 11 of 30 methylprednisolone-treated patients progressed to the primary endpoint (P = .43). We observed no significant difference in mortality between treatment groups (P = .41). There was a trend toward more severe disease in placebo recipients at entry. More subjects in the placebo group experienced SAEs (P = .02). There were no SAEs clearly related to methylprednisolone administration, and methylprednisolone did not increase viral load. CONCLUSIONS: Although methylprednisolone appears to be safe, it did not provide significant clinical benefit to patients. Our results do not support the use of methylprednisolone for HCPS. CLINICAL TRIALS REGISTRATION: NCT00128180. es_CL
dc.format.extent 9 es_CL
dc.language.iso en_US es_CL
dc.publisher Oxford University Press es_CL
dc.subject hantavirus es_CL
dc.subject hantavirus cardiopulmonary syndrome es_CL
dc.subject hantavirus pulmonary syndrome es_CL
dc.subject methylprednisolone es_CL
dc.subject clinical trial es_CL
dc.title High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial es_CL
dc.type Artículo es_CL

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account